Table 1. General Description of Adverse Events (N=128 Individual Cases).

Category	N (%)
Age
Not documented	1 (1)
0-23 months	48 (37)
2-3 years	25 (20)
4-8 years	23 (18)
9-13 years	14 (11)
14-18 years	17 (13)
Race
Not documented	80 (63)
Non-Hispanic white	14 (11)
Hispanic	12 (9)
African American	2 (2)
Asian	8 (6)
Other	12 (9)
Gender
Male	55 (43)
Female	55 (43)
Not documented	18 (14)
Time of Exposure
Prenatal	10 (8)
Postnatal	118 (92)
Main Adverse Event Reported*
Neurological (seizures, CNS depression, lethargy)	45 (35)
Gastrointestinal (nausea, vomiting, diarrhea)	18 (14)
Liver toxicity and jaundice	14 (11)
Cardiovascular/Hematological (hypertension, blood toxicity)	13 (10)
Dermatological (rash, burns)	12 (9)
Respiratory (coughing, respiratory depression)	9 (7)
Endocrine/Reproductive/Renal	8 (6)
Cyanosis	6 (5)
Neonatal withdrawal (drugs or alcohol)	2 (2)
Anaphylactic shock	1 (1)
Route of Administration
Unintentional oral ingestion	46 (36)
Intentional oral ingestion	37 (29)
Topically applied	22 (17)
Multiple modes	2 (2)
Not specified	2 (2)
Unintentional exposure to skin	1 (1)
Contaminated or Adulterated Products
Contaminated products reported in cases	6 (5)
Adulterated products reported in cases	2 (2)
Documentation of testing herb in lab	41 (32)
Documentation of lab work on patient	102 (80)
Documentation of exposure to heavy metals
Leads	9 (7)
Arsenic	2 (2)
None	117 (91)
Disposition
Resolution of symptoms following hospitalization	90 (70)
Resolution of symptoms with medications or outpatient therapy	18 (14)
Death	9 (7)
Disability	7 (6)
Organ transplantation	3 (2)
Not documented	1 (1)
Location of Case
United States	40 (31)
Europe (continental)	26 (20)
Asia	21 (17)
Australia	14 (11)
Great Britain	9 (7)
India Canada	6 (5) 5 (4)
Africa	3 (2)
Central America	3 (2)
Unknown	1(1)

^*This reflects the main clinical adverse event in case. Cases may have other symptoms reported.